Zetia is currently a $3 billion drug from MRK. It treats LDL cholesterol for those that are statin intolerant, and is combined with statins. It's a pill. ETC-1002 has shown to be more effective than Zetia both as a stand alone therapy or when taken with a statin. Also, when combining Zetia and ETC-1002, patients see a 48% reduction in LDL. All oral.
If Zetia is a $ 3 billion drug, what is ETC-1002?
Complicating matters are the REGN and AMGN drugs (needles) that will hit market later this year.
If the street starts to believe this is a multi-billion drug, how long do you think this will stay down?
Fair points. This could happen. Based n my research, this would be a huge buying opportunity and it will not stay down too long.
Maybe. Or maybe it's up $20 tomorrow. Or maybe it's taken out in a week. MRK's Zetia does $3-$4 billion or so in annual sales. ETC-1002 beats in it on every metric.
Zetia and ETC-1002, when combined, achieve almost 50% reduction in LDL. It would capture all of the statin intolerant market, and beat out REGN and AMGN drugs because all oral. Plus ETC-1002 superior to Zetia as an additive to statins.
They can combine Zetia with ETC-1002 and the combo reduces cholesterol almost as much as a statin - with less side effects. Othewise they will be forced to compete with ETC-1002, and ETC-1002 looks like the winner.
What is this drug's potential market? REGN and AMGN drugs supposedly $10 billion. This will be priced cheaper and probably only get a slice. So what is the annual sales target here?
4? I was only aware of possibly 3. Can you list? Thanks. Also, your previous post would be helpful if there was a link to the report you cited.
Does this designation by the FDA mean that there is a high probability that the drug will be approved in the end? Or is it simply that the drug addresses an unmet need with no indication of approval probability?
I thought that either MRK or ABBV was working on a single pill cocktail as well. Are you sure this is not the case? MRK? I am long GILD, but would like to get longer with a little more convincing. Thanks.
I am long GILD. Just wondering to what extent others have insight about the potential impact of new HCV drugs from MRK and ABBV. Thoughts? Likely or possible impact to GILD?
I owned as lot of FB and GILD into the bell. I saw both sets of earnings, and both were good. I was less worried about GILD. FB rose, and I thought I hit a homer. Then GILD sank. I have absolutely no idea why this stock isn't up AH.
Is the market concerned with the pipeline? Is Sovaldi susceptible to competition sooner than thought? I am lost here. We're talking about a forward PE of 9 or 10 and the company is buying back stock like crazy.
I want top line growth. They delivered big time. I WANT them to reinvest in future growth. Will be glad to hold from the $9 level. Good luck.
from the article....
In any case, Yahoo's deal with Yelp was long overdue. "Yahoo needed to do this investment a long time ago. The platform was just rotting," said a former member of Yahoo's local search team.
He said that local search in the US market was barely keeping up, and that international efforts were largely ignored. What's worse, the local-search technology itself had differed from global market to market, making it difficult to to execute on plans. Like many of Yahoo's woes, it was mainly a legacy problem: The platform for the, say, Korean market would be different from the platform for the US market, because of the siloed way those platforms evolved separately from each other.
Asked to estimate what a possible revenue share could be, the former Yahoo employee posited that it would be heavily in favor of Yelp, since it comes into the situation with more power thanks to the company's elevated cachet, helped by licensing deals with Microsoft, mentioned above, and Apple, which uses its content in Apple Maps. The person, who had knowledge of past Yahoo revenue share deals, guessed that the agreement could be lopsided to the tune of 70 percent Yelp, 30 percent Yahoo.
Yahoo decline to comment on the reported partnership. Financial terms, of course, have not been reported. But whatever they are, for Yahoo, it's worth it.
Seems there has to be something in this for YELP, correct? YHOO has large mobile footprint.